Doxylamine/pyridoxine controlled-release

Drug Profile

Doxylamine/pyridoxine controlled-release

Alternative Names: Diclectin; Diclegis; Doxylamine succinate/pyridoxine hydrochloride; Pyridoxine/doxylamine

Latest Information Update: 29 Sep 2016

Price : $50

At a glance

  • Originator Duchesnay Inc
  • Developer Alliance Pharma plc; Duchesnay Inc
  • Class Antiemetics; Picolines; Pyridines; Small molecules; Vitamins
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Morning sickness
  • Phase III Hyperemesis gravidarum

Most Recent Events

  • 13 Sep 2016 Alliance Pharma in-licenses doxylamine/pyridoxine controlled-release from Duchesnay in nine EU countries, including Germany, France and italy
  • 13 Sep 2016 Alliance Pharma announces intention to submit MAA to nine EU countries, including Germany, France and Italy in 2018
  • 11 May 2015 Doxylamine/pyridoxine is still in phase III trials for Hyperemesis gravidarum in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top